BioGaia AB Interim Management Statement – January – June 2022
SECOND QUARTER 2022 · Net sales amounted to SEK 288.1 million (203.1), an increase of SEK 85.0 million,...
Read moreBioGaia launches probiotic product to support children’s respiratory health
The US is the first market to launch BioGaia Pharax, which aims to strengthen the immune system and support children’...
Read moreBioGaia signs exclusive agreement in South Korea for the baby gut health range
BioGaia has extended its collaboration with Grace International, giving the company exclusive rights to market and sell its probiotic drops...
Read moreNew number of shares and votes in BioGaia AB (publ)
The number of shares and votes in BioGaia has increased during May due to the share split resolved by BioGaia’...
Read moreBioGaia starts its own distribution in Canada
Starting in 2023, BioGaia will be selling probiotics under its own management in Canada. Following the acquisition of Nutraceutics in...
Read moreBioGaia® Osfortis® winner of the NutraIngredients Awards 2022
We are proud to announce that our probiotic for bone health, Osfortis, is the winner of the 2022 NutraIngredients Awards...
Read moreRecord date for share split in BioGaia AB (publ) determined as 19 May 2022
At BioGaia’s Annual General Meeting held earlier today, on 6 May 2022, it was resolved on a share split...
Read moreAnnual General Meeting of BioGaia
The Annual General Meeting of BioGaia AB (publ) on 6 May 2022 voted, among other things, to approve the following...
Read more